Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Commentary|Articles|February 12, 2025
Supplements and Featured Publications
- Perspectives on FDA Oncology Approvals and Withdrawals That Shaped 2024: A Year in Review Roundup
- Volume 1
- Issue 1
Over a Dozen FDA Approvals in 2024 Changed the Lung Cancer Field
Author(s)Megan Hollasch
Fact checked by: Caroline Seymour
This full list of 2024 FDA approvals in lung cancer features insights from experts who sat down with us throughout the year to discuss their significance.
Advertisement
Advertisement
It was a particularly eventful year in the non–small cell lung cancer (NSCLC) field with 11 FDA approvals, but that wasn't all in the lung cancer space. The regulatory body greenlit 2 agents for patients with small cell lung cancer (SCLC) and 1 regimen for those with malignant pleural mesothelioma.
Related to this article
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
Advertisement
Advertisement